Medtech startup Onc.AI collects $25m in Series A financing

MassMutual and Action Potential Venture Capital led the round.

  • Other investors in the round included Life Extension Ventures, Blue Venture Fund, Accomplice, Digitalis Ventures and KdT Ventures
  • In conjunction with the financing, MassMutual’s David Diaz-Casariego and Action Potential Venture Capital’s Juan-Pablo Mas will join the Onc.AI’s board of directors
  • Onc.AI said the funds raised will support commercialization of its novel digital clinical management solution focused on immuno-oncology therapies

Onc.AI, a San Francisco and Waterloo, Ontario-based medical technology startup developing a novel digital clinical management solution focused on immuno-oncology, has raised $25 million in Series A financing.

MassMutual and Action Potential Venture Capital led the round. Other participants included Life Extension Ventures, Blue Venture Fund, Accomplice, Digitalis Ventures, and KdT Ventures.

“Having first learned about Onc.AI through a leading precision-oncology expert, we are thrilled to partner with an exceptional team and help the company as they aim to serve medical oncologists and cancer patients broadly,” said David Diaz-Casariego, a portfolio manager of alternative investments at MassMutual, in a statement.

Onc.AI said the funds raised will support commercialization of its novel digital clinical management solution focused on immuno-oncology therapies.

In conjunction with the financing, MassMutual’s Diaz-Casariego and Action Potential Venture Capital’s Juan-Pablo Mas will join the Onc.AI’s board of directors.